Tumor necrosis factor inhibitor
Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication
... Objectives: After treatment failure with a tumor necrosis factor inhibitor (TNFi), patients with rheumatoid arthritis (RA) can switch to another TNFi (TNFi cyclers) or to a targeted di[r] ...
9
Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study
... TNF inhibitor therapy. The results of rheumatoid factor (RF), anti- cyclic citrullinated peptide antibody (anti-CCP), and erythrocyte sedimentation rate (ESR) tests were ob- tained as part of patient ...
7
Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort
... The results were very similar in patients with a clinical diagnosis of axSpA made by their treating rheumatolo- gist and those fulfilling the ASAS classification criteria for axSpA. The presentation of patients with ...
8
Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry
... a tumor necrosis factor inhibitor (TNFi) following (1) inadequate response to a conventional synthetic disease-modifying antirheumatic drug (first-line biologic agent) and (2) inadequate ...
9
An Adenovirus Inhibitor of Tumor Necrosis Factor Alpha-Induced Apoptosis Complexes with Dynein and a Small GTPase
... Adenoviruses (Ad) code for immunoregulatory and cytokine regulatory proteins, one of which is the early region 3, 14.7-kDa protein (Ad E3-14.7K), which has been shown to inhibit tumor necrosis factor ...
5
Concurrent treatment with a tumor necrosis factor-alpha inhibitor and veno-venous extracorporeal membrane oxygenation in a post-hematopoietic stem cell transplant patient with idiopathic pneumonia syndrome: a case report
... A tumor necrosis factor-alpha inhibitor, etanercept, has been reported to be a promising treatment option for post-HSCT patients with IPS; however, the phase III clinical trial of etanercept ...
6
Tofacitinib for the treatment of tumor necrosis factor α inhibitor refractory esophageal Crohn’s disease: a case report
... described; they are steroid-sparing and treat more distal disease if present [5, 9]. There is one case report on the successful use of thalidomide [7]. There are been several case reports commenting on the use of ...
5
Invasive Salmonellosis by the Very Rare Salmonella choleraesuis in a Returning Traveler on a Tumor Necrosis Factor-α Inhibitor
... Salmonella choleraesuis is one of the least commonly reported nontyphoidal salmonellae in the United States, accounting for only 0.08% and ranking lower than 20th place among all human source salmonellosis reported to ...
5
Cellular Responses to Tumor Necrosis Factor
... and necrosis are initiated by TNF receptor I (TNF-RI) clustering and TRADD recruitment (Boldin et ...caspase inhibitor zVAD does not block TNF-induced L929 cell death, but in fact dramatically enhances ...
13
Modulation of Tumor Necrosis Factor by Raf-1 Inhibitor as a Potential Suppressor of Hepatocellular Carcinoma
... RAF-1 inhibitor on HepG2 cells, number of living cells and cell representative images has been monitored in pre-treated ...RAF-1 inhibitor followed by overnight ...RAF-1 inhibitor showed negligible ...
8
Paradoxical response to disseminated non tuberculosis mycobacteriosis treatment in a patient receiving tumor necrosis factor α inhibitor: a case report
... Relapsing polychondritis (RP) is a rare systemic disorder characterized by inflammation of the bilateral auricular or tracheal cartilage. Standard treatments for RP include immunosuppressive agents such as ...
5
Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor α inhibitors
... key factor in predicting response after a switch to an alternative biologic drug is the reason for discontinuation of the prior ...TNF-a inhibitor treatment, only a few reported response rates for groups of ...
15
Targeting Mycobacterium tuberculosis Tumor Necrosis Factor Alpha Downregulating Genes for the Development of Antituberculous Vaccines
... TNF-enhancing M. tuberculosis mutants promote macro- phage apoptosis upon infection. Apoptosis of M. tuberculosis- infected macrophages is beneficial to the host in that the process can kill tubercle bacilli and the ...
15
Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor alpha, and transforming growth factor beta
... activator inhibitor (PAI-1) gene expression was studied in vivo employing a murine model ...growth factor-beta (TGF-beta) increased the steady-state levels of PAI-1 mRNA within 3 h in all tissues ...
9
Protective effect of etanercept, an inhibitor of tumor necrosis factor-α, in a rat model of retinal ischemia
... cells after binding to its receptor [6]. Previous studies have shown increased TNF- α production in in vitro and in vivo ischemia models [3, 7, 8] and have demonstrated that neutralization of TNF- α by intravitreal TNF- ...
6
Key words
... In this study, the effects of a tumor necrosis factor-alpha (TNF- α ) inhibitor (etanercept) on peripheral nerve damage and the ultrastructure of the sciatic nerve and gastrocnemius mus[r] ...
9
The Role of Death Domains Superfamily in Multiple Sclerosis Pathogenesis
... transcription factor c-jun to induce inflam- matory ...(Tumor necrosis factor), TNFR1 (Tumor necrosis factor receptor 1), TRADD (TNFR-associated death domain), TRAF 2 ...
11
Effect of Tumor Necrosis Factor on Body Systems
... TNF promotes the inflammatory response, which in turn causes many of the clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, crohn's disease, psoriasis and ...
15
Characterization in vitro of a human tumor necrosis factor binding protein A soluble form of a tumor necrosis factor receptor
... Results from biosynthetic labeling of cells with 35S-cysteine followed by immunoprecipitation with anti-TNF-BP indicated that TNF-BP is formed and released at the cell surface by cleavag[r] ...
8
The role of human T lymphocyte monocyte contact in inflammation and tissue destruction
... Scheme of the relationship between chronic inflammation, acute-phase proteins and homeostasis of cytokines. The liver produces both apolipoprotein (apo) A-I and serum amyloid A (SAA). IL-1 β and TNF- α differentially ...
8